{
  "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
  "docSlug": "c241ac9edd2443452257949ce0a73d65",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 61,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 20,
  "notes": "The chart illustrates the correlation between the peak of HBI0101 cells and the subsequent drop in dFLC, a marker for AL Amyloidosis.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/17",
  "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
  "deckJsonHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920.json",
  "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.5,
        "x": 0.25,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Dual-axis line chart showing HBI0101/mL Blood and dFLC (mg/L) over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90dcf840-eb04-48d9-9686-509eb5fe115e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.3,
        "y": 0.2
      },
      "kind": "legend",
      "text": "HBI0101/mL Blood (blue), dFLC (mg/L) (red)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bbedad39-b859-4611-9af6-cdcd77ef3b00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "paragraph",
      "text": "*dFLC (=involved FLC-uninvolved FLC)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef3d98f0-5800-45de-b1ad-241764f2c4a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.02,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: NXC-201 (formerly known as HBI0101). Nexcella ASGCT Presentation Los Angeles 2023. E. Lebel et al. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis, International Myeloma Society 20th Annual Meeting, 2023.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b98ba820-593f-4358-946c-520dbc9b8981",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "N-GENIUS Technology Platform – NXC-201 rapidly eliminates diseased AL Amyloidosis plasma cells and exits within ~ 30 days (2/2)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "efe78c28-7ae6-43ee-85bb-abc8157c4777",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Visual emphasis",
      "slug": "visual-emphasis",
      "agent": null,
      "layer": "slide",
      "matchId": "cbd98edf-8353-4e11-a04b-36808d14be82",
      "evidence": "The use of a dual-axis line chart effectively communicates the rapid elimination of plasma cells.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 17,
      "from": 10,
      "beatId": "7f3ecbba-6032-4531-bb7e-529e9174ab66",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Desire",
      "beatSlug": "aida-desire",
      "evidence": "The competitive analysis, solution advantages, and clinical data create desire for the technology",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}